Venus Remedies has soared 9% to Rs 270 after reporting a robust 56% year-on-year (yoy) jump in net profit at Rs 16.06 crore for the third quarter ended December 31, 2012 (Q3) on back of higher
“The company’s net sales increased by 18% to Rs 113 crore for the quarter ended December 2012 compared to Rs 96 crore for the corresponding quarter last year,” a research-based global pharmaceutical company said in a filing.
Operating profit margins has improved by almost 200 basis points yoy to 27.1% from 25.37%.
The stock opened at Rs 252 and touched high of Rs 285 on NSE. A combined 138,897 shares have changed hands on the counter in early morning trades against an average sub 100,000 shares that were traded daily in past two weeks.
“The company’s net sales increased by 18% to Rs 113 crore for the quarter ended December 2012 compared to Rs 96 crore for the corresponding quarter last year,” a research-based global pharmaceutical company said in a filing.
Operating profit margins has improved by almost 200 basis points yoy to 27.1% from 25.37%.
The stock opened at Rs 252 and touched high of Rs 285 on NSE. A combined 138,897 shares have changed hands on the counter in early morning trades against an average sub 100,000 shares that were traded daily in past two weeks.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%